Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
TAMARACK
A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors
- NCT05551117 ↗
- Terminated
- MacroGenics
- Focused
We haven't built an HCP commentary report on TAMARACK (vobramitamab duocarmazine in metastatic castration-resistant prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on TAMARACK so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 2 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2, Open-label, Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
- Phase
- Phase 2
- Status
- Terminated
- Conditions
- Castration-Resistant Prostatic Cancer; Androgen-Independent Prostatic Cancer; Androgen-Insensitive Prostatic Cancer; Androgen-Resistant Prostatic Cancer; Hormone Refractory Prostatic Cancer; Anal Cancer; Anal Neoplasm; Carcinoma, Squamous Cell of Head and Neck; Head and Neck Squamous Cell Carcinoma; Laryngeal Squamous Cell Carcinoma; Oral Squamous Cell Carcinoma; Malignant Melanoma; Melanoma; Non-small Cell Lung Cancer; Non-small Cell Carcinoma; Small-cell Lung Cancer; Small Cell Carcinoma
- Interventions
- vobramitamab duocarmazine 2.0 mg (Arm A); vobramitamab duocarmazine 2.7 mg (Arm B); vobramitamab duocarmazine; Abiraterone; Enzalutamide
- Arms
- Part 1: MGC018 2.0 mg (Arm A) · Experimental
- Part 1: MGC018 2.7 mg (Arm B) · Experimental
- Part 2 · Experimental
- Part 1: Control Arm · Active comparator
- Enrollment
- 192
- Primary outcomes
- Part 1: Six-month Radiographic Progression Free Survival (rPFS) as Determined by the Investigator
- Part 2: Objective Response Rate (ORR) Per Investigator Assessment of Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 Criteria
- Sponsor
- MacroGenics
- Start
- Jun 13, 2023
- Primary completion
- Jul 4, 2024
- Results posted
- Yes
- Registry record
- NCT05551117 · updated Feb 9, 2026